FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignancy characterized by blood cell morphological dysplasia, ineffective clonal hematopoiesis, and risk of transformation to secondary acute myeloid leukemia (sAML). A number of genetic abnormalities have been identified in MDS and sAML, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Schieber, Michael, Marinaccio, Christian, Bolanos, Lyndsey C., Haffey, Wendy D., Greis, Kenneth D., Starczynowski, Daniel T., Crispino, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538974/
https://www.ncbi.nlm.nih.gov/pubmed/33024076
http://dx.doi.org/10.1038/s41408-020-00362-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538974/
https://www.ncbi.nlm.nih.gov/pubmed/33024076
http://dx.doi.org/10.1038/s41408-020-00362-7

Ejemplares similares